FUJIFILM Corporation (President: Kenji Sukeno) has succeeded in stably encapsulating the anti-cancer agent topotecan*1, approved for the treatment of several solid cancers, in newly invented liposome. When preclinical studies in mice were conducted using a drug where topotecan was encapsulated in...

News
RESEARCH RESULTS FOR FF-10832, A NOVEL LIPOSOME DRUG CANDIDATE FOR IMPROVEMENT OF PHARMACOLOGICAL EFFICACY THROUGH SELECTIVE DELIVERY OF ANTI-CANCER AGENT TO TUMORS
FUJIFILM Corporation (President: Kenji Sukeno) has announced the drug release mechanism of continuous action in tumors for the anti-cancer agent FF-10832, currently undergoing Phase I clinical trials in the United States. In addition, it has also been observed that improved pharmacological...
FUJIFILM ANNOUNCES LAUNCH OF FUJIFILM TOYAMA CHEMICAL
October 1, 2018 - FUJIFILM Corporation (President: Kenji Sukeno) announces the launch of FUJIFILM Toyama Chemical Co., Ltd (President: Junji Okada) on October 1, 2018. The company will engage in the research, development, manufacture and sale of diagnostic and therapeutic drugs. FUJIFILM Toyama...
Fujifilm Accelerates New Drug Development for Diagnostic and Therapeutic Drugs Through the Merger of Group Companies to Form FUJIFILM Toyama Chemical Co., Ltd.
FUJIFILM Holdings Corporation (President: Kenji Sukeno) today announced it plans to mergeTOYAMA CHEMICAL CO., LTD., a company that conducts the research, development, manufacture, and sales of small molecule pharmaceutical products, and FUJIFILM RI Pharma Co., Ltd., a company that conducts the...
Fujifilm Starts a U.S. Phase I Clinical Trial of Anti-Cancer Agent FF-10832 on Advanced Solid Tumors
FUJIFILM Corporation (President: Kenji Sukeno) announced the start of a U.S. Phase I clinical trial of the anti-cancer agent FF-10832 for advanced solid tumors. FF-10832 is a liposome-based agent in which the existing water-soluble anti-cancer agent gemcitabine*1 is encapsulated in liposomes by...
ANNOUNCEMENT ON THE START OF PATIENT ENROLLMENT FOR PHASE III CLINICAL STUDY IN JAPAN OF THE ANTIVIRAL DRUG FAVIPIRAVIR FOR IXODID TICK-BORNE INFECTIOUS DISEASE, SERIOUS FEVER WITH THROMBOCYTOPENIA SYNDROME (SFTS)
Toyama Chemical Co., Ltd. (Head Office: Shinjuku-ku, Tokyo; President: Junji Okada), a FUJIFILM Company, has announced that it has started to enroll patients for phase III clinical study in Japan of the antiviral drug favipiravir for ixodid tick-borne infectious disease, serious fever with...